share_log

VistaGen Therapeutics analyst ratings

VistaGen Therapeuticsのアナリストの評価

Benzinga Analyst Ratings ·  2022/07/26 09:00
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/26/2022 Maxim Group Downgrades Buy → Hold
07/22/2022 William Blair Downgrades Outperform → Market Perform
05/20/2021 4981.87% Baird → $9 Initiates Coverage On → Outperform
02/18/2021 3287.92% Jefferies → $6 Initiates Coverage On → Buy
01/04/2021 William Blair Upgrades Market Perform → Outperform
10/08/2020 3287.92% Aegis Capital → $6 Initiates Coverage On → Buy
08/28/2019 William Blair Initiates Coverage On → Outperform
07/22/2019 295.26% Chardan Capital $22 → $0.7 Downgrades Buy → Neutral
06/27/2018 3287.92% Maxim Group → $6 Initiates Coverage On → Buy
05/24/2018 3287.92% Oppenheimer → $6 Initiates Coverage On → Outperform

VistaGen Therapeutics Questions & Answers

What is the target price for VistaGen Therapeutics (VTGN)?

The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on July 26, 2022. The analyst firm set a price target for $0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for VistaGen Therapeutics (VTGN)?

The latest analyst rating for VistaGen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and VistaGen Therapeutics downgraded their hold rating.

When is the next analyst rating going to be posted or updated for VistaGen Therapeutics (VTGN)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VistaGen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VistaGen Therapeutics was filed on July 26, 2022 so you should expect the next rating to be made available sometime around July 26, 2023.

Is the Analyst Rating VistaGen Therapeutics (VTGN) correct?

While ratings are subjective and will change, the latest VistaGen Therapeutics (VTGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price VistaGen Therapeutics (VTGN) is trading at is $0.18, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする